Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Amortization of Deferred Charges (2020 - 2025)

Marimed (MRMD) has disclosed Amortization of Deferred Charges for 5 consecutive years, with $30000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 66.67% to $30000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $48000.0, a 88.6% decrease, with the full-year FY2024 number at $73000.0, down 80.05% from a year prior.
  • Amortization of Deferred Charges was $30000.0 for Q1 2025 at Marimed, up from $18000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $366000.0 in Q4 2023 to a low of -$14000.0 in Q3 2024.
  • A 4-year average of $92217.4 and a median of $30000.0 in 2025 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 95.08% in 2024, then skyrocketed 66.67% in 2025.
  • Marimed's Amortization of Deferred Charges stood at $176522.0 in 2021, then skyrocketed by 107.34% to $366000.0 in 2023, then crashed by 95.08% to $18000.0 in 2024, then soared by 66.67% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Amortization of Deferred Charges are $30000.0 (Q1 2025), $18000.0 (Q4 2024), and -$14000.0 (Q3 2024).